Japan Could Become The First Country To Eradicate HIV

Updated Mar 7, 2025 | 05:00 PM IST

SummaryThe idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Japan Could Become The First Country To Eradicate HIV

Credits: Canva

Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

End of Article

ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Updated Nov 18, 2026 | 05:04 PM IST

SummaryIndia is facing widespread antibiotic resistance, with several drugs showing low effectiveness against bacteria such as E. coli, Klebsiella pneumoniae and Salmonella. The ICMR's 2025 report also flags resistance to powerful antibiotics, including carbapenems, across participating hospitals.
ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Credit: iStock

Several antibiotics used to treat infections caused by E. coli and Klebsiella pneumoniae—bacteria linked to pneumonia, urinary tract and bloodstream infections—are showing low susceptibility in India, with resistance also reported to powerful drugs such as carbapenems, according to a new Indian Council of Medical Research (ICMR) report.

The newly released ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 assesses the distribution of bacterial pathogens and their susceptibility to different antibiotics.

The surveillance covers Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, as well as Gram-positive bacteria such as Staphylococcus aureus and Enterococcus species.

For the first time, the report included data from 34 secondary-care hospitals, highlighting that antibiotic resistance is a concern beyond large, specialised hospitals.

The findings underscore the need for better diagnostics, responsible antibiotic use and stronger infection prevention.

"Antibiotic resistance is no longer a distant threat—it is affecting patients and families across India," Dr Neha Rastogi Panda, Senior Consultant, Infectious Diseases, Fortis Hospital, Gurugram, told HealthandMe.

Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

Key Findings From The ICMR Report

The report highlighted several concerning resistance patterns across bacterial pathogens, including:

1. E. coli: Low susceptibility to cefotaxime and ceftazidime

The report showed that susceptibility of E. coli isolates to third-generation cephalosporins was low, with only 18.4% and 24.7% susceptible to cefotaxime and ceftazidime, respectively.

Low susceptibility was also observed among isolates from outpatient department (OPD) patients, suggesting that resistance to these antibiotics is widespread in the community and indicating a high prevalence of antibiotic-blocking enzymes.

2. K. pneumoniae: Low susceptibility to piperacillin-tazobactam and carbapenems

K. pneumoniae showed an alarmingly high resistance profile, with only 29.2% susceptible to piperacillin-tazobactam, 23–27% to third-generation cephalosporins, and only 35–40% to carbapenems.

Amikacin susceptibility was limited to 44.5%, while susceptibility to ceftazidime-avibactam was 37.7%. Tigecycline showed higher susceptibility, at 79.3%.

3. E. coli: Ceftriaxone susceptibility falls in secondary-care hospitals

Ceftriaxone susceptibility declined from 39.8% in Category I to 28.0% in Category II and 11.5% in Category III hospitals, indicating a high prevalence of resistance to third-generation cephalosporins even in smaller hospitals.

Meropenem susceptibility also declined across the three categories, from 80.3% to 77.5% and 67.1%, respectively.

Read more: Nearly 1 In 2 Patients Die, Treatment Costs Rise By 46%: ICMR Study Reveals Impact Of Drug-Resistant Infections

4. Acinetobacter baumannii: High carbapenem resistance

A high prevalence of carbapenem resistance was observed among A. baumannii, with 91.1% of revived isolates exhibiting carbapenem resistance, highlighting a substantial therapeutic and infection-control challenge.

OXA-23 was the predominant carbapenemase determinant, with frequent detection of OXA-23 and NDM co-profiles.

5. Salmonella Typhi and Salmonella Paratyphi A: Very low ciprofloxacin susceptibility

Fluoroquinolone susceptibility was lowest among the antibiotics assessed for both pathogens. Ciprofloxacin susceptibility was observed in only 2.0% of S. Typhi isolates and 0.4% of S. Paratyphi A isolates.

How Can We Prevent Antibiotic Resistance?

Dr Rastogi Panda warned that every time an antibiotic is misused, it increases the risk of making future infections harder to treat.

She advised people to:

  • Never take antibiotics without a doctor's prescription.
  • Never share antibiotics or use leftover tablets.
  • Take antibiotics exactly as prescribed.
  • Remember that antibiotics do not work against viral infections such as colds and flu.

"Cancer patients, ICU patients, the elderly and those with weakened immunity are particularly vulnerable. Responsible antibiotic use, vaccination and good hand hygiene can save lives. Protect antibiotics today, so they protect us tomorrow," the expert said.

End of Article

White House Drops Heidi Overton’s Nomination For US FDA Chief

Updated Nov 18, 2026 | 10:58 AM IST

SummaryHeidi Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
White House Drops Heidi Overton’s Nomination For US FDA Chief

Credit: AP Photos

The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.

Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.

A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”

Republican Opposition Threatened Her Confirmation

Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA

The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.

Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.

Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.

What Went Wrong For Dr. Heidi Overton?

Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation

Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.

Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.

Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.

Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.

MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.

Who Is Dr. Heidi Overton?

Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.

She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.

She also served during Trump's first administration before joining the think tank.

Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.

FDA Continues Under Acting Leadership

The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.

The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.

End of Article

Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Updated Nov 18, 2026 | 09:34 AM IST

SummarySELLAS Life Sciences recently announced findings from their late-stage clinical trial in which they tested an experimental cancer vaccine for acute myeloid leukemia (AML).
Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Credit: AI image

Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.

Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.

The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.

What Is Acute Myeloid Leukemia?

Also read: Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.

Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.

Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.

What Did The Trial Find?

Also read: World Cervical Cancer Elimination Day 2026: WHO Calls For HPV Vaccination, Screening & Early Treatment

The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.

According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.

SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.

How Does The Leukemia Vaccine Work?

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.

The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.

GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.

In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.

Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.

Side Effects Of GPS

GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.

The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.

If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.

End of Article